• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性和慢性中心性浆液性脉络膜视网膜病变患者血管生成因子水平的失衡

Imbalance in the Levels of Angiogenic Factors in Patients with Acute and Chronic Central Serous Chorioretinopathy.

作者信息

Karska-Basta Izabella, Pociej-Marciak Weronika, Chrząszcz Michał, Kubicka-Trząska Agnieszka, Dębicka-Kumela Magdalena, Gawęcki Maciej, Romanowska-Dixon Bożena, Sanak Marek

机构信息

Department of Ophthalmology, Faculty of Medicine, Clinic of Ophthalmology and Ocular Oncology, Jagiellonian University Medical College, 31-070 Krakow, Poland.

Dobry Wzrok Ophthalmological Clinic, 80-402 Gdansk, Poland.

出版信息

J Clin Med. 2021 Mar 5;10(5):1087. doi: 10.3390/jcm10051087.

DOI:10.3390/jcm10051087
PMID:33807809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7961803/
Abstract

BACKGROUND

The pathogenesis of central serous chorioretinopathy (CSC) remains a subject of intensive research. We aimed to determine correlations between plasma levels of selected angiogenic factors and different forms of CSC.

METHODS

Eighty patients were enrolled in the study including 30 with a chronic form of CSC, 30 with acute CSC, and 20 controls. Presence of active CSC was determined by fluorescein angiography (FA), indocyanine green angiography (ICGA), and swept-source optical coherence tomography (SS-OCT). Plasma concentrations of angiopoietin-1, endostatin, fibroblast growth factor, placental growth factor (PlGF), platelet-derived growth factor (PDGF-AA), thrombospondin-2, vascular endothelial growth factor (VEGF), VEGF-D, and pigment epithelium-derived factor were measured, and the results were compared between groups. Additionally, mean choroidal thickness (CT) was measured in all patients.

RESULTS

Levels of angiopoietin-1 ( = 0.008), PlGF ( = 0.045), and PDGF-AA ( = 0.033) differed significantly between the three groups. Compared with the controls, VEGF ( = 0.024), PlGF ( = 0.013), and PDGF-AA ( = 0.012) were downregulated in the whole CSC group, specifically PDGF-AA ( = 0.002) in acute CSC and angiopoietin-1 ( = 0.007) in chronic CSC. An inverse correlation between mean CT and VEGF levels was noted in CSC patients ( = -0.27, = 0.044).

CONCLUSIONS

Downregulated angiopoietin-1, VEGF, PDGF-AA, and PlGF levels may highlight the previously unknown role of the imbalanced levels of proangiogenic and antiangiogenic factors in the pathogenesis of CSC. Moreover, downregulated VEGF levels may suggest that choroidal neovascularization in CSC is associated with arteriogenesis rather than angiogenesis.

摘要

背景

中心性浆液性脉络膜视网膜病变(CSC)的发病机制仍是深入研究的课题。我们旨在确定特定血管生成因子的血浆水平与不同形式的CSC之间的相关性。

方法

80名患者纳入本研究,其中30例为慢性CSC患者,30例为急性CSC患者,20例为对照组。通过荧光素血管造影(FA)、吲哚菁绿血管造影(ICGA)和扫频光学相干断层扫描(SS-OCT)确定活动性CSC的存在。测量血管生成素-1、内皮抑素、成纤维细胞生长因子、胎盘生长因子(PlGF)、血小板衍生生长因子(PDGF-AA)、血小板反应蛋白-2、血管内皮生长因子(VEGF)、VEGF-D和色素上皮衍生因子的血浆浓度,并在组间比较结果。此外,测量所有患者的平均脉络膜厚度(CT)。

结果

三组之间血管生成素-1(P = 0.008)、PlGF(P = 0.045)和PDGF-AA(P = 0.033)水平存在显著差异。与对照组相比,整个CSC组中VEGF(P = 0.024)、PlGF(P = 0.013)和PDGF-AA(P = 0.012)下调,急性CSC中PDGF-AA(P = 0.002)和慢性CSC中血管生成素-1(P = 0.007)尤为明显。CSC患者中观察到平均CT与VEGF水平呈负相关(P = -0.27,P = 0.044)。

结论

血管生成素-1、VEGF、PDGF-AA和PlGF水平下调可能凸显了促血管生成和抗血管生成因子水平失衡在CSC发病机制中先前未知的作用。此外,VEGF水平下调可能表明CSC中的脉络膜新生血管形成与动脉生成而非血管生成有关。

相似文献

1
Imbalance in the Levels of Angiogenic Factors in Patients with Acute and Chronic Central Serous Chorioretinopathy.急性和慢性中心性浆液性脉络膜视网膜病变患者血管生成因子水平的失衡
J Clin Med. 2021 Mar 5;10(5):1087. doi: 10.3390/jcm10051087.
2
Role of Plasma Angiopoietin-1 and VEGF Levels as Potential Biomarkers in Chronic Central Serous Chorioretinopathy with Macular Neovascularization.血浆血管生成素-1 和 VEGF 水平作为慢性中心性浆液性脉络膜视网膜病变伴黄斑新生血管潜在生物标志物的作用。
Int J Mol Sci. 2024 Oct 6;25(19):10748. doi: 10.3390/ijms251910748.
3
Changes in Plasma VEGF and PEDF Levels in Patients with Central Serous Chorioretinopathy.中心性浆液性脉络膜视网膜病变患者血浆血管内皮生长因子和色素上皮衍生因子水平的变化
Medicina (Kaunas). 2021 Oct 5;57(10):1063. doi: 10.3390/medicina57101063.
4
Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA).经扫频源光学相干断层扫描血管造影(SS OCTA)诊断的新生血管性和非新生血管性慢性中心性浆液性脉络膜视网膜病变(CSC)的临床评估
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1581-1590. doi: 10.1007/s00417-019-04297-z. Epub 2019 Apr 29.
5
Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy.急性和慢性中心性浆液性脉络膜视网膜病变患者血浆细胞因子水平的改变。
Acta Ophthalmol. 2021 Mar;99(2):e222-e231. doi: 10.1111/aos.14547. Epub 2020 Jul 23.
6
Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy.上调的血管生成细胞因子与慢性中心性浆液性脉络膜视网膜病变脉络膜异常的关系。
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5924-5931. doi: 10.1167/iovs.18-25517.
7
Choroidal thickness measurement by enhanced depth imaging and swept-source optical coherence tomography in central serous chorioretinopathy.通过增强深度成像和扫频源光学相干断层扫描测量中心性浆液性脉络膜视网膜病变的脉络膜厚度
BMC Ophthalmol. 2014 Nov 25;14:145. doi: 10.1186/1471-2415-14-145.
8
Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy.光学相干断层扫描评估中心性浆液性脉络膜视网膜病变的脉络膜视网膜厚度及造影改变。
Ophthalmology. 2012 Aug;119(8):1666-78. doi: 10.1016/j.ophtha.2012.02.021. Epub 2012 Apr 21.
9
Predictors of anti-VEGF efficacy in chronic central serous chorioretinopathy based on intraocular cytokine levels and pigment epithelium detachment subtypes.基于眼内细胞因子水平和色素上皮脱离亚型的慢性中心性浆液性脉络膜视网膜病变抗VEGF疗效的预测因素
Acta Ophthalmol. 2022 Nov;100(7):e1385-e1394. doi: 10.1111/aos.15109. Epub 2022 Feb 4.
10
Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变中光学相干断层扫描血管造影与荧光素和吲哚菁绿血管造影的对比研究结果
Lasers Surg Med. 2018 Dec;50(10):987-993. doi: 10.1002/lsm.22952. Epub 2018 Jun 12.

引用本文的文献

1
Analysis of cytokine profiles in aqueous humor based on optical coherence tomography in pachychoroid spectrum diseases.基于光学相干断层扫描技术对厚脉络膜谱系疾病房水中细胞因子谱的分析
Sci Rep. 2025 Jul 1;15(1):20639. doi: 10.1038/s41598-025-04130-0.
2
Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma.蛋白酪氨酸磷酸酶受体B(PTPRB)中的罕见基因变异与中心性浆液性脉络膜视网膜病变、静脉曲张和青光眼有关。
Nat Commun. 2025 May 3;16(1):4127. doi: 10.1038/s41467-025-58686-6.
3
Role of Plasma Angiopoietin-1 and VEGF Levels as Potential Biomarkers in Chronic Central Serous Chorioretinopathy with Macular Neovascularization.

本文引用的文献

1
Quality of life of patients with central serous chorioretinopathy - a major cause of vision threat among middle-aged individuals.中心性浆液性脉络膜视网膜病变患者的生活质量——中年人群视力威胁的主要原因。
Arch Med Sci. 2020 Jan 29;17(3):724-730. doi: 10.5114/aoms.2020.92694. eCollection 2021.
2
Central Serous Chorioretinopathy Classification.中心性浆液性脉络膜视网膜病变分类
Pharmaceuticals (Basel). 2020 Dec 30;14(1):26. doi: 10.3390/ph14010026.
3
Complement Activation Products and Cytokines in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
血浆血管生成素-1 和 VEGF 水平作为慢性中心性浆液性脉络膜视网膜病变伴黄斑新生血管潜在生物标志物的作用。
Int J Mol Sci. 2024 Oct 6;25(19):10748. doi: 10.3390/ijms251910748.
4
Risk Factors and VEGF, hs-CRP, and ESR in Central Serous Chorioretinopathy.中心性浆液性脉络膜视网膜病变的危险因素与血管内皮生长因子、高敏C反应蛋白及红细胞沉降率
J Ophthalmol. 2024 Sep 19;2024:9322594. doi: 10.1155/2024/9322594. eCollection 2024.
5
The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.炎症在中心性浆液性脉络膜视网膜病变中的作用:从机制到治疗前景
Front Pharmacol. 2024 May 21;15:1200492. doi: 10.3389/fphar.2024.1200492. eCollection 2024.
6
Rare genetic variation in VE-PTP is associated with central serous chorioretinopathy, venous dysfunction and glaucoma.血管内皮蛋白酪氨酸磷酸酶(VE-PTP)的罕见基因变异与中心性浆液性脉络膜视网膜病变、静脉功能障碍和青光眼有关。
medRxiv. 2024 May 9:2024.05.08.24307013. doi: 10.1101/2024.05.08.24307013.
7
Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China.玻璃体内注射抗血管内皮生长因子药物阿柏西普与亚阈值微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变:中国携带型维替泊芬短缺的替代治疗方案。
Ann Med. 2023 Dec;55(1):2227424. doi: 10.1080/07853890.2023.2227424.
8
Biometric Risk Factors for Central Serous Chorioretinopathy.中心性浆液性脉络膜视网膜病变的生物统计学危险因素。
Ophthalmol Ther. 2023 Apr;12(2):1327-1338. doi: 10.1007/s40123-023-00687-z. Epub 2023 Feb 25.
9
Diagnostic and Therapeutic Challenges in a Patient with Radiation Retinopathy Complicated by Corticosteroid-Induced Central Serous Chorioretinopathy.放射性视网膜病变合并皮质类固醇诱导性中心性浆液性脉络膜视网膜病变患者的诊断和治疗挑战。
Medicina (Kaunas). 2022 Jun 28;58(7):862. doi: 10.3390/medicina58070862.
10
β-Toxin Exerts Anti-angiogenic Effects by Inhibiting Re-endothelialization and Neovessel Formation.β-毒素通过抑制再内皮化和新血管形成发挥抗血管生成作用。
Front Microbiol. 2022 Feb 3;13:840236. doi: 10.3389/fmicb.2022.840236. eCollection 2022.
补体激活产物和细胞因子在肥厚脉络膜新生血管病变和新生血管性年龄相关性黄斑变性中的作用。
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):39. doi: 10.1167/iovs.61.13.39.
4
Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review.大疱性中心性浆液性脉络膜视网膜病变:一种罕见且非典型的中心性浆液性脉络膜视网膜病变。系统评价
Pharmaceuticals (Basel). 2020 Aug 28;13(9):221. doi: 10.3390/ph13090221.
5
Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options.厚脉络膜新生血管病变:一种属于厚脉络膜谱系的1型脉络膜新生血管病变——发病机制、影像学及现有治疗选择
Int Ophthalmol. 2020 Dec;40(12):3577-3589. doi: 10.1007/s10792-020-01522-1. Epub 2020 Jul 30.
6
Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy.急性和慢性中心性浆液性脉络膜视网膜病变患者血浆细胞因子水平的改变。
Acta Ophthalmol. 2021 Mar;99(2):e222-e231. doi: 10.1111/aos.14547. Epub 2020 Jul 23.
7
Differences in anti-endothelial and anti-retinal antibody titers: implications for the pathohysiology of acute and chronic central serous chorioretinopathy.抗血管内皮细胞和抗视网膜抗体滴度的差异:对急性和慢性中心性浆液性脉络膜视网膜病变发病机制的影响。
J Physiol Pharmacol. 2020 Apr;71(2). doi: 10.26402/jpp.2020.2.07. Epub 2020 Jul 13.
8
Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration.初治渗出型年龄相关性黄斑变性患者对血管内皮生长因子治疗无应答和快速耐受。
J Physiol Pharmacol. 2019 Oct;70(5). doi: 10.26402/jpp.2019.5.13. Epub 2020 Jan 30.
9
Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变消退后的视力和视网膜形态损害
BMC Ophthalmol. 2019 Jul 25;19(1):160. doi: 10.1186/s12886-019-1171-5.
10
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.中心性浆液性脉络膜视网膜病变:迈向基于证据的治疗指南。
Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15.